Our store location is now open with huge sales on RUO products. Monday, Wednesday and Friday 11 a.m. to 6 p.m., Saturday 11 a.m. to 4 p.m.
Marvel Peptide USA
CJC-1295 + Ipamorelin
CJC-1295

CJC-1295 + Ipamorelin

Supplied as a lyophilized powder in a sealed vial, for laboratory research use only.

$27.00 per vial

Strengths and prices

StrengthPrice per vial AvailabilityBatch
10 mg $27.00 In stock CP-2607-0039

Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.

What it is

A blend of two synthetic peptides in one vial: a CJC-1295 growth hormone releasing hormone analogue and ipamorelin, a ghrelin receptor agonist.

Identity

TypeBlend of two synthetic peptides
ComponentsCJC-1295 and ipamorelin
AmountsAs stated on the label and the certificate of analysis

A blend of two synthetic peptides lyophilized together in one vial. CJC-1295 is a 29-amino-acid analogue of GRF(1-29) with four amino-acid substitutions and an amidated C-terminus. The form with DAC adds a lysine carrying a maleimidopropionamide group, C165H269N47O46, 3647.2 g/mol (PubChem CID 91971820); the form without DAC has no PubChem record. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, which contains the non-proteinogenic residues aminoisobutyric acid and D-2-naphthylalanine, C38H49N9O5, 711.9 g/mol (PubChem CID 9831659). The two forms of CJC-1295 differ in mass, so the mass spectrometry result on the certificate shows which one a batch contains. Neither peptide contains cysteine. It is supplied as a lyophilized powder in a sealed vial.

What the published research covers

The published literature covers the components one at a time. Studies of this combination as a single preparation are few or absent.

The two peptides in this vial have separate literatures. CJC-1295 was developed by a Montreal group as a long-lasting version of growth hormone releasing factor, GRF(1-29). In a 2005 rat study they compared three derivatives built to bond to serum albumin; the best, CJC-1295, a tetrasubstituted GRF(1-29) with a reactive maleimide group on an added C-terminal lysine, produced a fourfold larger growth hormone response than GRF(1-29) over two hours and remained in plasma beyond 72 hours (Jetté, 2005). In two placebo-controlled trials in healthy adults, a single administration raised mean growth hormone concentrations 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days (Teichman, 2006). Both studies concern the albumin-binding form, CJC-1295 with DAC. The same chain without the reactive group, often called modified GRF 1-29 and the form a blend of this kind usually contains, has no published studies of its own under those names.

Ipamorelin is a pentapeptide described in 1998 as the first selective growth hormone secretagogue. It released growth hormone from rat pituitary cells with a potency similar to GHRP-6, and in swine it did not raise ACTH, cortisol, FSH, LH, prolactin or TSH (Raun, 1998). In healthy men given ipamorelin at five infusion rates, growth hormone rose in a single episode peaking at about 40 minutes, and the terminal half-life of ipamorelin was about two hours (Gobburu, 1999). A phase 2 trial in 114 patients after bowel resection found no significant difference from placebo in the time to the first tolerated meal (Beck, 2014).

No published study has examined CJC-1295 and ipamorelin together, in either form of CJC-1295; a PubMed search returns only reviews that list them side by side. The case for pairing a GHRH analogue with a ghrelin receptor agonist rests on their acting at two different pituitary receptors, and the nearest experimental evidence uses other peptides: in eight healthy men, GHRH(1-29) and GHRP-2 given together produced a larger growth hormone response than GHRP-2 alone but no larger than the sum of the two separate responses, and the authors could not demonstrate synergy (Tiulpakov, 1995). Nothing has been published on the two peptides lyophilized together, so the certificate of analysis, which confirms each component by mass spectrometry, is the only document that speaks to a given batch.

Regulatory status

Not approved by the FDA for any use. Supplied for laboratory research only.

Testing and documentation

A blend is tested for each component: mass spectrometry confirms that every peptide named on the label is present, and HPLC reports the purity. The certificate of analysis for the batch is reachable from the code on the vial.

Questions laboratories ask

What is in a vial?
Two peptides lyophilized together: a CJC-1295 growth hormone releasing hormone analogue and ipamorelin. The vial is listed at 10 mg on the product page; the label and the certificate of analysis for the batch state the amount of each component.
Is the CJC-1295 in this blend the form with DAC?
Blends of this kind usually contain CJC-1295 without DAC, also called modified GRF 1-29. The two forms differ in mass, so the mass spectrometry result on the certificate of analysis shows which form a batch contains.
Has the combination been studied?
No study of this combination has been published. The published work covers CJC-1295 and ipamorelin separately, in rats, swine and small human studies.
How is a blend tested?
By an independent laboratory, for each component: mass spectrometry confirms that both peptides named on the label are present, and HPLC reports the purity. The QR code on the vial opens the certificate for that exact batch.
Who can order, and how does it ship?
Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.

References

  1. Tiulpakov AN et al. (1995). GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clinical Endocrinology. PubMed 7586605
  2. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. PubMed 9849822
  3. Gobburu JV et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. PubMed 10496658
  4. Jetté L et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. PubMed 15817669
  5. Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. PubMed 16352683
  6. Beck DE et al. (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. PubMed 25331030

How it ships

Next day
Dispatched from Montana on all orders, packed and tracked.
One vial
The minimum order. You pay by card at checkout, or by invoice before the order ships.
Your batch
The certificate of analysis for the batch you receive is on the vial and on this site.

Ordering

Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.

Research use only

This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement

More from the catalog

All peptides, strengths and prices →